Posted by Michael Wonder on 21 Oct 2021
FDA grants breakthrough device designation for Biological Dynamics’ early stage pancreatic cancer detection test
20 October 2021 - Designation provides expedited regulatory review of Exo-PDAC, a liquid biopsy assay, built on the company’s Verita platform to detect pancreatic ductal adenocarcinoma earlier in high-risk adults.
Biological Dynamics today announced that the U.S. FDA has granted breakthrough device designation for its liquid biopsy assay, Exo-PDAC.
The test is designed to provide early detection for pancreatic ductal adenocarcinoma, one of the most aggressive and lethal forms of cancer worldwide.
